Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?

Pediatric Hematology and Oncology

Volumn 27, Issue 7, 2010, Pages 503-516

  Dincaslan, Handan Ugur ^a   Yavuz, Gulsan ^a   Unal, Emel ^a   Tacyildiz, Nurdan ^a   Ikinciogullari, Aydan ^a   Dogu, Figen ^a   Guloglu, Deniz ^a   Yuksek, Nazmiye ^b   Ertem, Ulya ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

Author keywords

Angiogenesis; Hodgkin's lymphoma; Leukemia; Non Hodgkin's lymphoma; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANGIOGENESIS; ARTICLE; BONE MARROW; BURKITT LYMPHOMA; CANCER REGRESSION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; INFANT; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HODGKIN DISEASE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77957229982     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.493574     Document Type: Article

References (71)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Dong X, Han ZC, Yang RC. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol. 2007;62:105-118. (Pubitemid 46584811)
3. Bellamy WT, Richter L. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-733. (Pubitemid 29076074)
4. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
5. Bhatti SS, Kumar L, Dinda AK, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computarized image analyzer in the assesment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol. 2006;81:649-656. (Pubitemid 44306822)
6. De Raeve H, VanMarck E, Van Camp B, et al. Angiogenesis and the role of bonemarrow endothelial cells in haematological malignancies. Histol Histopathol. 2004;19:935-950. (Pubitemid 38855074)
7. Negaard HFS, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2009;23:162-169.
8. Lundberg LG, Hellström-Lindberg E, Kanter-Lewensohn L, et al. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res. 2006;30:247-253. (Pubitemid 43053217)
9. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;19:2039-2048.
10. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 2003;81:20-31. (Pubitemid 36207880)
11. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309.
12. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644. (Pubitemid 30210544)
13. De Bont ESJM, Rosati S, Jacobs S, et al. Increased bone marrow vascularization in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor. Br J Haematol. 2001;113:296-304. (Pubitemid 32523131)
14. Mirshahi P, Rafii A, Vincent L, et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia. 2009;23:1039-1048.
15. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
16. Fiedler W, Graeven U, Ergün S, et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997;11:1234-1237. (Pubitemid 27387298)
17. Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302-1310.
18. Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial cell growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870-1875. (Pubitemid 27132100)
19. Gerber HP,Malik AK, Solar GP, et al. VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-958.
20. Hiramatsu A, Miwa H, Shikami M, et al. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma. 2006;47:89-95. (Pubitemid 43101730)
21. Jeha S, Smith FO, Estey E, et al. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk Res. 2002;26:399-402. (Pubitemid 34143055)
22. Avramis IA, Panoysan EH, Dorey F, et al. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standart-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962. Clin Cancer Res. 2006;12: 6978-6984. (Pubitemid 44974492)
23. Pule MA, Gullman C, Dennis D, et al. Increased angiogenesis in bone marrow of children with acute lymphoblastic leukemia has no prognostic significance. Br J Haematol. 2002;118:991-998. (Pubitemid 35025961)
24. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-821. (Pubitemid 27106153)
25. Schneider P, Vasse M, Sbaa-Ketata E, et al. The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis. Leukemia. 2001;15:1143-1145. (Pubitemid 32717290)
26. Faderl S, Do KA, Johnson MM, et al. Angiogenic factors may have a different prognostic role in adult lymphoblastic leukemia. Blood. 2005;106:4303-4307. (Pubitemid 41775940)
27. Ji RC. Lymph node lymphangiogenesis: a new concept formodulating tumormetastasis and inflammatory process. Histol Histopathol. 2009;24:377-384.
28. Ribatti D. Lymphangiogenesis in haematological malignancies. Leuk Res. 2009;33:753-755.
29. Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol. 2005;17:611-616. (Pubitemid 41566417)
30. Kadowaki I, Ichinohasama R, Harigae H, et al. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol. 2005;130:869-877. (Pubitemid 43899728)
31. Giles FJ, Vose JM, Do KA. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004;28:595-604. (Pubitemid 38543196)
32. Salven P, Orpana A, Teerenhovi L. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non- Hodgkin's lymphoma: a single institution study of 200 patients. Blood. 2000;96:3712-3718.
33. Paydas S, Seydaoglu G, Ergin M, et al. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma. 2009;50:366-373.
34. Younes A. Angiogenesis in lymphoma: a short review. Curr Mol Med. 2005;5:609-613. (Pubitemid 41824224)
35. Vacca A, Ribatti D, Roncali L, et al. Angiogenesis in B-cell lymphoproliferative disease. Biological and clinical studies. Leuk Lymphoma. 1995;20:27-38. (Pubitemid 26007426)
36. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:538-590.
37. Golub TR, Arceci RJ. Acute myelogenous leukemia. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:591-645.
38. Hudson MM, Onciu M, Donaldson SS. Hodgkin lymphoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:695-721.
39. Link MP, Weinstein HJ. Malignant non-hodgkin lymphomas in children. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:722-747.
40. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87:4979-4989. (Pubitemid 26189839)
41. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548-2555.
42. Creutzig U, Berthold F, Boos J, et al. AML-BFM-Studien-Gruppe. Improved treatment results in children with AML: results of study AML-BFM 93. Klin Padiatr. 2001;213:175-185. (Pubitemid 32801569)
43. Sandlund JT, Pui CH, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23:1127-1130.
44. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Classification. Cancer Res. 1971;31:1860-1861.
45. Murphy SB. Current concepts in cancer: childhood non-Hodgkin's lymphoma. N Engl J Med. 1978;299:1446-14478.
46. Schellong G, Hörnig I, Brämswig J, et al. Significance of procarbazine in the chemotherapy of Hodgkin's disease-a report of the Cooperative Therapy Study DAL-HD-85. Klin Padiatr. 1988;200:205-213.
47. Griffin TC, Bowman WP, Winick NJ, et al. Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood: further experience with Total Therapy B. Med Ped Oncol. 1994;23: 393-399.
48. Reiter A, Shrappe M, Ludwig W, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoplasmacytic lymphoma: a BFM group report. Blood. 2000;95:416-421. (Pubitemid 30041651)
49. Matsumoto Y, Nomura K, Kanda-Akano Y, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma. 2003;44:879-882. (Pubitemid 36410998)
50. Liersh R, Schliemann C, Bieker R, et al. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk Res. 2008;32:954-961. (Pubitemid 351389550)
51. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGFC, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298. (Pubitemid 26029207)
52. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis invivo. Proc Natl Acad Sci U S A. 1998;95:14389-14394. (Pubitemid 28549377)
53. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002;99:2179-2184. (Pubitemid 34525504)
54. Bautz F, Rafii S, Kanz L, et al. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells: possible role in the hematopoietic microenvironment. Exp Hematol. 2000;28:700-706. (Pubitemid 30398527)
55. Litwin C, Leong KG, Zapf R, et al. Role of microenvironment in promoting angiogenesis in acute myeloid leukemia. Am J Hematol. 2002;70:22-30.
56. Kusumanto YH, Dam WA, Hospers GAP, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-287.
57. Kut C, Gabhann FM, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97:978-985. (Pubitemid 47519292)
58. Koomagi R, Zintl F, Sauerbrey A, et al. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res. 2001;7:3381-3384. (Pubitemid 33069969)
59. Lyu CJ, Rha SY, Won SC. Clinical role of bonemarrow angiogenesis in childhood acute lymphocytic leukemia. Yonsei Med J. 2007;48:171-175. (Pubitemid 46711745)
60. Yetgin S, Yenicesu I, Cetin M, et al. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42:83-88. (Pubitemid 32700925)
61. Aref S, Salama O, Shamaa S, et al. Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology. 2007;12:319-324. (Pubitemid 47180659)
62. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J ExpMed. 2002;196:1497-1506. (Pubitemid 35424943)
63. Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;19:894-900. (Pubitemid 40861996)
64. Jorgensen JM, Sorensen FB, Bendix K, et al. Angiogenesis in non-Hodgkin's lymphoma:clinicopathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 2007;48:584-595. (Pubitemid 46487768)
65. Hazar B, Paydas S, Zorludemir S, et al. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:2089-2093. (Pubitemid 37369649)
66. Niitsu N, Okamato M, Nakamine H, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleulin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2002;68:91-100. (Pubitemid 34478273)
67. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non- Hodgkin's lymphoma. Br J Haematol. 1999;106:504-509. (Pubitemid 29450678)
68. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683.
69. Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683.
70. Citak EC, Oguz A, Karadeniz C, et al. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract. 2008;204:89-96.
71. De Jonge HJM, Weidenaar AC, ter Elst A, et al. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res. 2008;14:924-930. (Pubitemid 351231177)